ID

34300

Descripción

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01166282

Link

https://clinicaltrials.gov/show/NCT01166282

Palabras clave

  1. 16/1/19 16/1/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

16 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Enthesitis Related Arthritis (ERA) NCT01166282

Eligibility Enthesitis Related Arthritis (ERA) NCT01166282

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of enthesitis related arthritis (era) as defined by international league of associations for rheumatology (ilar);
Descripción

ID.1

Tipo de datos

boolean

disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;
Descripción

ID.2

Tipo de datos

boolean

inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.
Descripción

ID.3

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
any ilar juvenile idiopathic arthritis (jia) subtype other than era;
Descripción

ID.4

Tipo de datos

boolean

psoriasis or a history of psoriasis in the patient or first-degree relative;
Descripción

ID.5

Tipo de datos

boolean

presence of immunoglobulin m (igm) rheumatoid factor;
Descripción

ID.6

Tipo de datos

boolean

presence of systemic jia,
Descripción

ID.7

Tipo de datos

boolean

history of inflammatory bowel disease, previous biologic therapy including anti-tnf therapy with a potential impact on pediatric era;
Descripción

ID.8

Tipo de datos

boolean

infection(s) requiring treatment with iv anti-infectives within 30 days prior to baseline or oral anti-infectives within 14 days prior to baseline
Descripción

ID.9

Tipo de datos

boolean

Similar models

Eligibility Enthesitis Related Arthritis (ERA) NCT01166282

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
diagnosis of enthesitis related arthritis (era) as defined by international league of associations for rheumatology (ilar);
boolean
ID.2
Item
disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;
boolean
ID.3
Item
inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
any ilar juvenile idiopathic arthritis (jia) subtype other than era;
boolean
ID.5
Item
psoriasis or a history of psoriasis in the patient or first-degree relative;
boolean
ID.6
Item
presence of immunoglobulin m (igm) rheumatoid factor;
boolean
ID.7
Item
presence of systemic jia,
boolean
ID.8
Item
history of inflammatory bowel disease, previous biologic therapy including anti-tnf therapy with a potential impact on pediatric era;
boolean
ID.9
Item
infection(s) requiring treatment with iv anti-infectives within 30 days prior to baseline or oral anti-infectives within 14 days prior to baseline
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial